Enavate Sciences GP, LLC - Oct 15, 2024 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)

Role: 10%+ Owner
Signature: Enavate Sciences GP, LLC, By: /s/ James P. Boylan, Manager
Stock symbol: CAMP
Transactions as of: Oct 15, 2024
Transactions value $: $14,999,996
Form type: 4
Date filed: 10/17/2024, 04:15 PM
Previous filing: Oct 10, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CAMP	Common Stock	Conversion of derivative security		+2.42M			2.42M	Oct 15, 2024	By Everest Aggregator, LP	F1, F2
transaction	CAMP	Common Stock	Purchase	$15M	+1.36M	+56.3%	$11.00	3.79M	Oct 15, 2024	By Everest Aggregator, LP	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CAMP	Series B Preferred Stock	Conversion of derivative security		-27.2M	-100%		0	Oct 15, 2024	Common Stock	2.42M		By Everest Aggregator, LP	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
F2	Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

Content

Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.

Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.